Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim reports positive new lung cancer data for Giotrif

Boehringer Ingelheim reports positive new lung cancer data for Giotrif

14th October 2016

Boehringer Ingelheim has announced new clinical trial data showing how its drug Giotrif can help reduce the risk of lung cancer death.

The LUX-Lung 7 trial directly compared the efficacy and safety of the second-generation EGFR-directed therapy Giotrif with an established first-generation therapy in the first-line treatment of patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).

A reduction in the risk of death of 14 percent was observed for patients treated with Giotrif compared to the alternative, while the median survival rate of Giotrif recipients was 27.9 months compared to 24.5 months for those receiving the other drug.

These findings reaffirm the fact that Boehringer Ingelheim's drug can significantly improve progression-free survival rates and time to treatment failure, as well as delivering an increased overall response rate without compromising overall health-related quality of life, safety and tolerability.

Dr Mehdi Shahidi, vice-president and global head of medicine for oncology at Boehringer Ingelheim, said: "We believe that the totality of the results of the LUX-Lung 7 trial data helps differentiate second-generation afatinib from first-generation therapies for these patients, adding to the growing body of evidence that reinforces its distinct treatment benefits."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801826756-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.